OBSAH
ODBORNÁ SYMPOZIA ........................................................................................................................ 10
Sympozium společnosti pro biologickou psychiatrii – emoční dysregulace napříč
psychickými poruchami ......................................................................................................................... 10
Limity a možnosti léčby antipsychotiky a neurostimulačními metodami ................................................12
Neprávem opomíjený a obávaný klozapin .............................................................................................12
Neinvazivní mozková stimulace (NIBS) napříč neuropsychiatrií – od výzkumu
ke klinické praxi ......................................................................................................................................13
Sympózium Psychofarmakologickej sekcie SPsS ..................................................................................14
Mikrobiom a možnosti jeho interakce s psychofarmaky .........................................................................16
Novinky v léčbě poruch příjmu potravy ...................................................................................................17
Ketaminem asistované psychoterapie (KAP) v léčbě celého neurotického spektra ..............................18
Nová vodítka psychiatrické společnosti ČLS JEP pro léčbu deprese ....................................................20
Intenzivní péče v psychiatrii ....................................................................................................................21
Psychedelika, problémové děti psychofarmakologie V: Stále problémové,
`nebo budoucnost? ................................................................................................................................22
Gerontopsychiatrie .................................................................................................................................23
Znepokojivé trendy v psychofarmakologii u dětí a adolescentů: Od nešťastné
psychopatologie k medicinalizaci ...........................................................................................................24
Děti, jejichž matky užívaly v těhotenství psychofarmaka: Medikovat, či nemedikovat
těhotné? ................................................................................................................................................ 25
Nové pokroky v oblasti VR terapie (terapie virtuální realitou): Ohlédnutí
za konferencí ICDVRAT 2024 ............................................................................................................... 26
Farmakodetektivky 2 ............................................................................................................................28
Neuropsychiatrické aspekty digitálních závislostí ................................................................................29
Psychedelika, problémové děti psychofarmakologie – neurobiologické okénko ..................................30
Inovace a výzvy v léčbě sexuálních dysfunkcí: od robotů po farmakologické přístupy ........................32
Zvýšenie endokanabinoidnej signalizácie ako cieľ pre farmakoterapiu
úzkostnýcha kognitívnych porúch ....................................................................................................... 33
Nárůst sérových hladin olanzapinu vlivem akutního zánětu ................................................................33
Vliv CB1 antagonisty / inverzního agonisty AM251 na metabolickou aktivitu P450:
`In vitro studie ..................................................................................................................................... 34
Vybrané génové varianty a odpoveď na liečbu escitalopramom u pacientov s diagnózou
depresívnej poruchy ........................................................................................................................... 34
Vztah mezi sérovou koncentrací 25(OH) vitaminu D, verbální pamětí a objemem
hipokampální šedé hmoty u pacientů s první epizodou schizofrenie ................................................. 34
Pravděpodobnostní kvantifikace trendu vlasového kortisolu pro dlouhodobé
monitorování terapie .......................................................................................................................... 35
Dynamika frontálního EEG jako indikátor odpovědi na antidepresivní léčbu:
Retrospektivní analýza pomocí Hurstova exponentu u pacientů s depresivní poruchou .................. 35
Medikační trajektorie antipsychotik a váhový přírůstek u prvotně hospitalizovaných
pacientů s první epizodou psychotického onemocnění ..................................................................... 36
VÝVĚSKOVÁ SDĚLENÍ .....................................................................................................................37
Preklinická P1–P11.................................................................................................................................37
Klinická K1–K16 .....................................................................................................................................41
Pohádky 1000+1 noci: interaktivně pojaté kazuistické střípky psychedelických ponorů
do nevědomého materiálu z více než tisíce ketaminových procesů na Klinice Psyon ...........................49
Algoritmus podávání off-label ketaminu v psychiatrii ................................................................................ 49
Práce s přepisem v imaginaci u transgeneračního traumatu .................................................................... 49
Deeskalace agitovaného pacienta ............................................................................................................ 50
Léčba závažných příznaků vybraných duševních poruch – EBM, umění, nebo magie?........................... 50
Farmakologická léčba ADHD u dospělých ................................................................................................ 50
CONTENTS
SCIENTIFIC SYMPOSIA ...........................................................................................................................10
Society for Biological Psychiatry Symposium– emotional dysregulation
acrosspsychiatric disorders ........................................................................................................................10
Limits and possibilities of treatment with antipsychotics and neurostimulation methods ......................... 12
Unjustly neglected and feared clozapine .................................................................................................. 12
Non-invasive brain stimulation (NIBS) across neuropsychiatry – from research
to clinical practice ......................................................................................................................................13
Symposium of the Psychopharmacological Section of the Slovak Psychiatric Society ............................ 14
The microbiome and its potential interactions with psychopharmacs ....................................................... 16
News in the treatment of eating disorders ................................................................................................. 17
Ketamine-assisted psychotherapy (KAP) in the treatment of the entire neurotic spectrum ...................... 18
New guidelines of Czech Psychiatric Society for treatment of depression ............................................... 20
Psychiatric intensive care ......................................................................................................................... 21
Psychedelics problem children of psychopharmacology V: Still problematic, or the future?..................... 22
Gerontopsychiatry .................................................................................................................................... 23
Disturbing Trends in Psychopharmacology in Children and Adolescents: From
unfortunate psychopathology to medicalization ....................................................................................... 24
Children whose mothers took psychopharmaceuticals during pregnancy: To medicate,
or not to medicate pregnant women? ....................................................................................................... 25
New advances in VR (virtual reality) therapy: A look back at the ICDVRAT 2024 conference ................. 26
Psychopharmacs detective stories 2nd .................................................................................................... 28
Neuropsychiatric aspects of digital addictions ......................................................................................... 29
Psychedelics, problem children of the psychopharmacology – neurobiological window ......................... 30
Innovations and challenges in the treatment of sexual dysfunctions: From robots
to pharmacological approaches ............................................................................................................... 32
Enhancement of endocannabinoid signaling as a target for pharmacotherapy
of anxiety and cognitive disorders ............................................................................................................ 33
Increase in serum olanzapine levels in acute inflammation ..................................................................... 33
Effect of the CB1 antagonist / inverse agonist AM251 on P450 metabolic activity:
An in vitro study ........................................................................................................................................ 34
Selected gene variants and escitalopram treatment response in patients
with depressive disorder ........................................................................................................................... 34
A relationship between 25(OH) vitamin D serum level, verbal memory and hippocampal
gray matter volume in first episode schizophrenia patients ...................................................................... 34
Probabilistic quantification of hair cortisol trend for long-term therapy monitoring ................................... 35
Frontal eeg dynamics as indicators of antidepressant response:
A Hurst exponent-based retrospective analysis in major depression disorder ......................................... 35
Trajectories of daily antipsychotic use and weight gain in people hospitalized
for first episode of psychosis .................................................................................................................... 36
Preclinical P1–P11 ...................................................................................................................................37
Clinical K1–K16 .................................................................................................................. .................... 41
Tales of 1000+1 nights: interactively conceived casuistic shards of psychedelic dives
into unconscious material from over a thousand of ketamine processes at the Psyon Clinic .................. 49
Algoritm for off-label use of ketamine in psychiatry................................................................................... 49
Working with imagery rescripting in transgenerational trauma ................................................................ 49
Deescalation of agitated patient .............................................................................................................. 50
Treatment of severe symptoms of selected mental disorders – EBM, art, or magic? ............................. 50
Pharmacological treatment of ADHD in adults ........................................................................................ 50
